CLB vs GFR
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CLB exhibits a concerning divergence between its current market price ($17.45) and its deterministic value markers, with a Piotroski F-Score of 4/9 indicating only stable health. The stock is trading at a significant premium to both its Graham Number ($9.04) and Intrinsic Value ($4.41), while experiencing a sharp YoY earnings decline of 31.60%. Despite a strong 1-year price rally, the underlying fundamentals—specifically the negative earnings growth and bearish technical trend—suggest the current valuation is unsustainable.
GFR presents a stark dichotomy between a fortress balance sheet and collapsing operational performance. While the Piotroski F-Score of 4/9 indicates stable but mediocre financial health, the company's near-zero debt (Debt/Equity 0.01) and P/B ratio of 0.92 provide a significant valuation floor. However, catastrophic revenue declines (-35.4% YoY) and a string of earnings misses (0/4 beats) suggest a severe deterioration in core business momentum. The stock is defensively undervalued per the Graham Number ($8.55) but fundamentally overpriced relative to its growth-based intrinsic value ($3.36).
Compare Another Pair
Related Comparisons
CLB vs GFR: Head-to-Head Comparison
This page compares Core Laboratories Inc. (CLB) and Greenfire Resources Ltd. (GFR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.